There are 2934 resources available
1867 - ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
Presenter: Ghassan Abou-Alfa
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
2389 - Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 ATTRACTION-3 Study
Presenter: Byoung Chul Cho
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
5059 - PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Presenter: Maha Hussain
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
3965 - CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ronald de Wit
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
2800 - IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Enrique Grande
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
5276 - ESMO-MCBS and Health Technology Assessment (HTA): Does value for physicians correspond to value for payers?
Presenter: Apoorva Ambavane
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
2243 - Change in Magnitude of Clinical Benefit, Overall Survival (OS) and Quality of Life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015.
Presenter: Aida Bujosa Rodríguez
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
5379 - Consistency of ESMO-MCBS scores with drug access recommendations in Catalonia
Presenter: Mercè Obach
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
3815 - Reimbursement Reality for Off-label use in cancer care – A systematic empirical investigation
Presenter: Amanda Herbrand
Session: Proffered Paper - Public policy
Resources:
Abstract
Slides
Webcast
Proffered Paper - Sarcoma - Invited Discussant LBA87
Presenter: Heikki Joensuu
Session: Proffered Paper - Sarcoma
Resources:
Slides
Webcast